Corporate HQ:
New York, NY
Founded in 2014, Base5 Biosciences conducts research to enable the development of novel therapeutics based on RNA demethylation pathways.
The company developed the first antibody-based methods for global N6-methyladenosine (m6A) mapping and has consistently been at the forefront of m6A research.
For more detailed information, please visit: www.base5bio.com
Co-founder and Scientific Advisory Board Chairman, Base5, Inc.
Professor of Pharmacology
Weill Cornell Medical College
Blavatnik Regional Award
Winner 2013
Recognized for uncovering mechanisms that control mRNA trafficking during brain development.
Dr. Jaffrey and his group developed the first method to map RNA base modifications such as m6A in the transcriptome. Dr. Jaffrey's group is developing new approaches to understand how m6A affects cellular function in normal and disease states.